GlassScriptPhysician profile
Rafael Moncayo
NPI 1538335997
$7,219.69
in general payments reported to CMS, 2019-2025
33 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $859 · 2021: $617 · 2022: $353 · 2023: $1,163 · 2024: $1,562 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,430.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,671.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $782.85 | 2019-2025 | |
| Lilly USA, LLC | $714.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $676.15 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $675.28 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $465.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.67 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.78 | 2019-2025 | Xifaxan |
| Allergan, INC. | $203.13 | 2019-2021 | |
| Amgen INC. | $143.95 | 2019-2025 | Repatha, Otezla, Otezla |
| Genentech USA, INC. | $128.03 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $126.65 | 2020-2025 | Contrave, Onzetra Xsail |
| Exact Sciences Corporation | $124.99 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $107.95 | 2019-2025 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $98.41 | 2023-2025 | Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $95.55 | 2019-2023 | Pancreaze |
| Merck Sharp & Dohme LLC | $84.12 | 2019-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Azurity Pharmaceuticals, INC. | $82.15 | 2024-2025 | Horizant, Azmiro |
| Sanofi Pasteur INC. | $54.07 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $51.67 | 2019-2020 | |
| Phadia US INC. | $42.72 | 2019 | |
| Astellas Pharma US INC | $38.82 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $35.94 | 2022 | |
| Axsome Therapeutics, INC. | $34.02 | 2025 | Sunosi |
| Esperion Therapeutics, INC. | $33.68 | 2021 | |
| Biogen, INC. | $32.05 | 2019 | |
| Dexcom, INC. | $27.07 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.34 | 2023 | |
| Hologic Sales and Service, LLC | $22.72 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.38 | 2025 | |
| Integra Lifesciences Corporation | $21.13 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Arbor Pharmaceuticals, INC. | $14.23 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.90 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Moncayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.